2002 |
ӰҵMedical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States.
|
2004 |
Ӱҵadopts the “Company with Committees” system.
ӰҵEurope Ltd. is established as a European regional headquarters (holding company) in London, the United Kingdom.
ӰҵPharmaceuticals India Pvt. Ltd. is established as a pharmaceutical sales subsidiary in Mumbai, India.
|
2005 |
ӰҵS.r.l is established as a pharmaceutical sales subsidiary in Milan, Italy.
ӰҵPharma AG is established as a pharmaceutical sales subsidiary in Zurich, Switzerland.
The Corporate Mission is added to the ӰҵArticles of Incorporation.
ӰҵAB is established as a pharmaceutical sales subsidiary in Stockholm, Sweden.
Honorary chairman and Eisai's second president Yuji Naito passes away at age 85.
|
2006 |
ӰҵAustralia Pty. Ltd. is established as a pharmaceutical sales subsidiary in Sydney, Australia.
Ӱҵrolls out its fifth mid-term plan, the “Dramatic Leap Plan.”
Ӱҵ(Singapore) Pte. Ltd. and ӰҵClinical Research Singapore Pte. Ltd. are established as a pharmaceutical sales subsidiary and clinical research subsidiary, respectively, in Singapore.
Ӱҵacquires four anticancer agents from Ligand Pharmaceuticals Inc. in the United States.
EF-ӰҵFarmacêutica, Unipessoal Lda. is established as a pharmaceutical sales subsidiary in Lisbon, Portugal.
|
2007 |
ӰҵManufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom.
Ӱҵacquires Morphotek Inc., a bioventure specialized in antibody research, in the United States.
ӰҵPharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India.
ӰҵSA/NV is established as a pharmaceutical sales subsidiary in Brussels, Belgium.
|
2008 |
Ӱҵacquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States.
ӰҵMachinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery.
Rheumatoid arthritis treatment Humira is launched in Japan.
|
2009 |
ӰҵGesmbH is established as a pharmaceutical sales subsidiary in Vienna, Austria.
The European Knowledge Centre opens as a European strategic base in Hertfordshire, the United Kingdom.
European Knowledge Centre
The ӰҵProduct Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D.
Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations.
The ӰҵKnowledge Centre, India opens as a manufacturing and process research base in Vizag, India.
ӰҵKnowledge Centre, India |
2010 |
The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award.
Koishikawa Knowledge Center
ӰҵLimited is established as a pharmaceutical sales subsidiary in Ontario, Canada.
Production headquarters transforms to a global “ӰҵDemand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing.
Ӱҵ(Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China.
Anticancer agent Halaven is launched in the United States.
Ӱҵsigns a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge.
H3 Biomedicine Inc. is established as a research subsidiary in the United States.
|
2011 |
The Great East Japan Earthquake strikes.
Ӱҵrolls out its sixth mid-term plan, “HAYABUSA.”
ӰҵParticipações Ltda. is established as a pharmaceutical sales subsidiary in São Paulo, Brazil.
Halaven is launched in Europe and Japan.
ӰҵLaboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.
|
2012 |
Ӱҵsigns the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.
Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ).
Antiepileptic agent Fycompa is launched in Europe.
|
2013 |
Limited Liability Company Ӱҵis established as a pharmaceutical sales subsidiary in Moscow, Russia.
Ӱҵco-establishes the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership to advance development of new health technologies for the developing world.
Ӱҵinitiates free of charge provision of diethylcarbamine tablets produced at its Vizag plant in India to WHO for use in the treatment of lymphatic filariasis.
|
2014 |
Fycompa is launched in the United States.
ӰҵChina Holdings Ltd. is established as a holding company in Suzhou, China.
|
2015 |
Anticancer agent Lenvima is launched in the United States, Japan and Europe.
Ӱҵcompletes acquisition of Chinese generic pharmaceutical company Liaoning Tianyi Biological Pharmaceutical Co., Ltd. (new trading name: Ӱҵ(Liaoning) Pharmaceutical Co., Ltd.)
|
2016 |
Ӱҵrolls out its seventh mid-term plan “EWAY2025.”
EA Pharma Co., Ltd. is established as a gastrointestinal specialty pharmaceutical company.
Fycompa is launched in Japan.
|
2017 |
Ӱҵjoins global partnership to address non-communicable diseases.
Ӱҵpledges continued support for lymphatic filariasis elimination.
Ӱҵcommits funding to the 2nd phase of Global Health Innovative Technology Fund activities.
Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded.
|
2018 |
Ӱҵagrees upon a strategic collaboration for Lenvima with Merck & Co., Inc., Kenilworth, N.J., U.S.A.
New Suzhou plant in China commences full-scale operation.
Lenvima (hepatocellular carcinoma) is launched in China.
|
2019 |
ӰҵCenter for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation.
G2D2
Parkinson’s disease treatment Equfina is launched in Japan.
Fycompa and Halaven are launched in China.
|
2020 |
The WHO Declares COVID-19 a Pandemic.
“NouKNOW” (pronounced “NOH-NOH”), a new tool for self-assessment of brain performance (brain health) is launched in Japan.
DAYVIGO (insomnia treatment) is launched in the United States and Japan.
ӰҵVietnam Co., Ltd. is established as a pharmaceutical sales subsidiary in Ho Chi Minh City, Vietnam.
Unlimit Health Limited is established in Shanghai, China.
|
2021 |
Ӱҵrolls out its eighth medium-term business plan "EWAY Future &Beyond".
Alzheimer’s disease treatment ADUHELM is granted accelerated approval and launched in the United States.
Ӱҵenters into a global strategic collaboration agreement with Bristol-Myers Squibb Company for MORAb-202.
The Tokyo Olympics take place.
ӰҵIsrael Ltd. is established as a pharmaceutical sales subsidiary in Tel Aviv, Israel.
Ӱҵcelebrates its 80th anniversary.
|
2022 |
Ӱҵand Biogen amend collaboration agreements on ADUHELM.
Ӱҵmakes Arteryex Inc., a company that plans and develops software, its subsidiary.
ӰҵPharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa.
Ӱҵsigns the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases.
Deep Human Biology Learning (DHBL), a new R&D organization, commences full-scale operation.
|
2023 |
Alzheimer’s disease treatment LEQEMBI is granted accelerated approval and launched in the United States.
Ӱҵcommits funding to the 3rd phase of Global Health Innovative Technology Fund.
LEQEMBI is granted traditional approval by the FDA.
Theoria technologies Co., Ltd. is established as a digital business company in Tokyo, Japan.
LEQEMBI is launched in Japan.
|